MicroRNAs in lipoprotein metabolism and cardiometabolic disorders. (March 2016)

• Record Type: Journal Article
• Authors: Rotllan, Noemi; Price, Nathan; Pati, Paramita; Goedeke, Leigh; Fernández-Hernando, Carlos
• Is Part Of: Atherosclerosis. Volume 246(2016)
• Page Start: 352
• Page End: 360
• Publication Date: 2016-03
• Subjects: microRNAs -- Atherosclerosis -- Lipid metabolism; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2016.01.025
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Circulating levels of low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) are two of the most important risk factors for the development of cardiovascular disease (CVD), the leading cause of death worldwide. Recently, miRNAs have emerged as critical regulators of cholesterol metabolism and promising therapeutic targets for the treatment of CVD. A great deal of work has established numerous miRNAs as important regulators of HDL metabolism. This includes miRNAs that target ABCA1, a critical factor for HDL biogenesis and reverse cholesterol transport (RCT), the process through which cells, including arterial macrophages, efflux cellular cholesterol for transport to and removal by the liver. The most well studied of these miRNAs, miR-33, has been demonstrated to target ABCA1, as well as numerous other genes involved in metabolic function and RCT, and therapeutic inhibition of miR-33 was found to increase HDL levels in mice and non-human primates. Moreover, numerous studies have demonstrated the beneficial effects of miR-33 inhibition or knockout on reducing atherosclerotic plaque burden. Even more recent work has identified miRNAs that regulate LDL cholesterol levels, including direct modulation of LDL uptake in the liver through targeting of the LDL receptor. Among these, inhibition of miR-128-1, miR-148a, or miR-185 was found to reduce plasma LDL levels, and inhibition of miR-185 was further demonstrated to reduce atherosclerotic plaque size in ApoE −/− mice. Due to their ability to target many different genes, miRNAs have the ability to mediate complex physiologic changes through simultaneous regulation of multiple interrelated pathways. Of particular importance for CVD, inhibition of miR-148a may prove an important therapeutic approach for combating dyslipidemia, as this has been demonstrated to both raise plasma HDL levels and lower LDL levels in mice by targeting both ABCA1 and LDLR, respectively. In this review we highlight recent advances in our understanding of how miRNAs regulate cholesterol metabolism and the development of atherosclerotic plaques and discuss the potential of anti-miRNA therapies for the treatment and prevention of CVD. Highlights: miR-33 regulates numerous physiological processes associated with HDL-C metabolism. ABCA1 expression is regulated post-transcriptionally by numerous miRNAs. miR-148a and miR-128-1 antagonism increases hepatic LDLR and ABCA1 expression. Inhibition of miR-148a and miR-128-1 decreases circulating LDL-C.